Recent Press Releases

GSK and Biological E. announce joint venture to develop combination vaccine for India and other developing countries

Issued: Monday 28 January 2013, London UK and Mumbai/Hyderabad, India GlaxoSmithKline (GSK) and Biological E Limited (Biological E.), a leading Indian vaccines company, today announced an agreement...

NIH-developed candidate dengue vaccine shows promise in early-stage trial

A candidate dengue vaccine developed by scientists at the National Institutes of Health has been found to be safe and to stimulate a strong immune response in most vaccine recipients, according to...

European Medicines Agency reviews hypothesis on Pandemrix and development of narcolepsy

No new concerns for Pandemrix or other vaccines on the basis of available evidence The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), at the request of the...

Novartis receives EU approval for Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe

Bexsero is indicated to help protect all age groups against meningococcal serogroup B (MenB) disease, including infants who are the most vulnerable[1] MenB disease is associated with a high...

U.S. FDA Approves Flublok®, the World's First Recombinant, Highly Purified, Egg-Free Influenza Vaccine

- The U.S. FDA approved Flublok for people 18-49 years old – making it the first recombinant vaccine for influenza available on the market. Approval for all people 18 years and above is...

Pivotal study in The Lancet shows potential of Novartis vaccine Bexsero® to help provide broad protection to infants against MenB

Pivotal study in The Lancet shows potential of Novartis vaccine Bexsero® to help provide broad protection to infants against MenB Phase III results show that Bexsero induced a robust immune...

WHO heralds "new phase" in the fight against neglected tropical diseases

WHO heralds "new phase" in the fight against neglected tropical diseases Sustained commitment key to reaching eradication and elimination targets by 2020 News release 16 January 2013 |...

Altravax, Inc. awarded $1.2 million to advance dengue vaccine and hepatitis therapeutic

Altravax, Inc. awarded $1.2 million to advance dengue vaccine and hepatitis therapeutic MolecularBreeding™ technology platform offers new approach to vaccines Fargo, ND and Sunnyvale, CA....

Pfizer Receives European Approval To Expand Use Of Prevenar 13 To Older Children And Adolescents Aged 6 To 17 Years For The Prevention Of Pneumococcal Disease

Pfizer Receives European Approval To Expand Use Of Prevenar 13 To Older Children And Adolescents Aged 6 To 17 Years For The Prevention Of Pneumococcal Disease Prevenar 13 is the First and Only...

MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech

MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech Follow-on agreement will lead to clinical trials WASHINGTON, DC and Blue Bell, PA (January 7, 2013)—The...

Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates

Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates SAN FRANCISCO, Jan.3, 2013 – Sutro Biopharma, a biopharmaceutical company developing a...

Immunovaccine Reports Positive Results from Ongoing Study of DepoVax™-Based Anthrax Vaccines

Immunovaccine Reports Positive Results from Ongoing Study of DepoVax™-Based Anthrax Vaccines - Potential to Induce Toxin Neutralizing Antibodies With a Single Dose - Shown to be Well-tolerated...

Emergent BioSolutions Secures Exclusive U.S. Commercial Rights to Next Generation Pandemic Influenza Vaccine Candidate

Emergent BioSolutions Secures Exclusive U.S. Commercial Rights to Next Generation Pandemic Influenza Vaccine Candidate Company takes important step forward as a BARDA Center for Innovation in...

Johns Hopkins Receives Funding for Cholera Vaccine Initiative

Johns Hopkins Receives Funding for Cholera Vaccine Initiative Released: 12/27/2012 8:00 AM EST Source: Johns Hopkins Bloomberg School of Public Health Newswise — The Johns Hopkins Bloomberg...

Genentech Announces FDA Approval of Tamiflu for the Treatment of Influenza in Infants

Genentech Announces FDA Approval of Tamiflu for the Treatment of Influenza in Infants -- First Medicine Approved to Treat Influenza in Infants Two Weeks of Age and Older -- SOUTH SAN FRANCISCO,...

New Process to Make One-Way Flu Vaccine Discovered

New Process to Make One-Way Flu Vaccine Discovered Dec. 18, 2012 — A new process to make a one-time, universal influenza vaccine has been discovered by a researcher at Georgia State...

GlycoVaxyn AG Announces Strategic Collaboration with GSK to Develop New Bacterial Vaccines using GlycoVaxyn's Bio-Conjugation Technology

GlycoVaxyn AG Announces Strategic Collaboration with GSK to Develop New Bacterial Vaccines using GlycoVaxyn's Bio-Conjugation Technology ZURICH-SCHLIEREN, Switzerland, Dec. 19, 2012 -- GlycoVaxyn...

FDA Approves GlaxoSmithKline's four-strain seasonal influenza vaccine for use in the US

FDA Approves GlaxoSmithKline's four-strain seasonal influenza vaccine for use in the US Issued Monday 17 December 2012, London UK GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S....

FDA Approves GlaxoSmithKline's four-strain seasonal influenza vaccine for use in the US

FDA Approves GlaxoSmithKline's four-strain seasonal influenza vaccine for use in the US Issued Monday 17 December 2012, London UK GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the U.S....

Sanofi Pasteur Launches Next Generation Japanese Encephalitis Vaccine in Thailand

Sanofi Pasteur Launches Next Generation Japanese Encephalitis Vaccine in Thailand BANGKOK, December 17, 2012 - New Japanese encephalitis vaccine indicated for children and adults - - About 3 billion...